Meyka Pro banner
Opus Genetics, Inc.

Opus Genetics, Inc. (IRD) Stock Overview

Explore Opus Genetics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

IRDNASDAQ
HealthcareBiotechnology
$5.73
$1.39(32.03%)
U.S. Market opens in NaNh NaNm

Opus Genetics, Inc. (IRD)

Meyka AI Score

Z

Key Financials

Market Cap473.1M
P/E Ratio-4.62
EPS (TTM)$-1.28
ROE11.48%
Fundamental Analysis

AI Price Forecasts

1 Month$5.09
3 Months$4.94
1 Year Target$5.88

IRD Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Opus Genetics, Inc. (NASDAQ: IRD) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Opus Genetics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of IRD on the NASDAQ shows an RSI of 76.19, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $5.88 for the NASDAQ listing.

Key metrics behind Opus Genetics, Inc.'s NASDAQ-traded stock include a P/E ratio of -4.62 and a market capitalization of 473.1M. Combined with our AI analysis, these give both institutional and retail investors a clear view of IRD on the NASDAQ.

Price Performance (NASDAQ: IRD)

1-Day Change
32.03%
5-Day Change
26.49%
1-Month Change
56.56%
3-Month Change
40.44%
6-Month Change
20.13%
Year-to-Date (YTD) Change
185.07%
1-Year Change
321.32%
3-Year Change
344.19%
5-Year Change
344.19%
All-Time (Max) Change
344.19%

Contact Information

248 957 9024
8 Davis Drive, Durham, NC, 27713

Company Facts

280 Employees
IPO DateJan 19, 2015
CountryUS
Actively Trading

Frequently Asked Questions